Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1816 to 1830 of 7682 results

  1. Subcutaneous belimumab for treating systemic lupus erythematosus in children aged 5 to 17 TS ID 11828

      Status ...

    Technology appraisal guidance
    Topic selection

  2. Dabrafenib, trametinib or both for treating BRAF V600 mutation-positive unresectable or metastatic melanoma in people aged 12 and over TS ID 11838

    Awaiting development [GID-TA11275] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  3. Dabrafenib with trametinib for adjuvant treatment of resected BRAF V600 mutation-positive melanoma in people aged 12 to 17 TS ID 11839

    Awaiting development [GID-TA11276] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  4. Invimestrocel for treating acute ischaemic stroke within 18 to 36 hours of onset TS ID 10190

    Awaiting development [GID-TA11283] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  5. Ceftobiprole medocaril for treating community- or hospital-acquired pneumonia in people 3 months to 17 years TS ID 11819

      Status ...

    Technology appraisal guidance
    Topic selection

  6. Baricitinib for treating moderate to severe atopic dermatitis in children and young people aged 2 to 17 [TS ID 10639]

      Status ...

    Technology appraisal guidance
    Topic selection

  7. NPJ5008 for treating malignant hyperthermia TS ID 11829

      Status ...

    Technology appraisal guidance
    Topic selection

  8. Semaglutide for treating obesity-related heart failure with preserved ejection fraction TS ID 11788

      Status ...

    Technology appraisal guidance
    Topic selection

  9. Aquablation robotic therapy for lower urinary tract symptoms caused by benign prostatic hyperplasia

    Awaiting development [GID-MT599] Expected publication date: TBC

    Medical technologies guidance
    Awaiting development

  10. CAEL-101 with standard care for untreated amyloid light chain amyloidosis TS ID 10666

    Awaiting development [GID-TA11182] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  11. DV7103 for treating cystinuria in people 6 months and over TS ID 10438

      Status ...

    Technology appraisal guidance
    Topic selection

  12. Palovarotene for treating flare ups of heterotopic ossification associated with fibrodysplasia ossificans progressiva [ID2721]

    In development [GID-HST10033] Expected publication date: TBC

    Highly specialised technologies guidance
    In development

  13. Letetresgene autoleucel for treating NY-ESO-1 advanced unresectable synovial sarcoma in people aged 10 and over or NY-ESO-1 advanced unresectable myxoid round cell liposarcoma in adults TS ID 10652

    Awaiting development [GID-TA11194] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  14. ABP-654 (ustekinumab biosimilar) for previously treated moderate to severe plaque psoriasis TS ID 11790

      Status ...

    Technology appraisal guidance
    Topic selection

  15. Niraparib with abiraterone acetate and prednisone for untreated hormone-relapsed metastatic prostate cancer TS ID 10523

    Awaiting development [GID-TA11114] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development